Shares in Asterias Biotherapeutics (NYSE:AST) jumped 11% today to $3.53 apiece after the company reported positive data for its AST-OPC1 progenitor cell therapy in patients with spinal cord injuries. The Phase 1/2A clinical trial includes 6 patients in the AIS-A 10 million cell cohort. The company’s AST-OPC1 progenitor cell therapy is derived from human embryonic […]